Effective Date: April 2014 Revision: September 29, Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers.

Similar documents
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board

managing or activities.

Preliminary Questionnaire

Research Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review

Standard Operating Procedures

SOP : Quality Assurance Inspections SCOPE RESPONSIBILITIES. APPROVAL AUTHORITY EFFECTIVE DATE May PURPOSE 2.

Good Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center

Dr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015

1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements

General Administration GA STANDARD OPERATING PROCEDURE ON SOPs: Preparing, Maintaining and Training

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

Investigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser

Regulatory Inspections

Unofficial copy not valid

General Administration GA STANDARD OPERATING PROCEDURE FOR Document Development and Change Control

EMA & FDA Inspections: Site perspective. Shandukani Research Centre

Standard Operating Procedures

Toward Greater Scientific Rigor

LOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP)

DANA-FARBER / HARVARD CANCER CENTER POLICIES FOR HUMAN SUBJECT RESEARCH TITLE:

1. INTRODUCTION 2. SCOPE 3. PROCESS

Office of Human Research Ethics/IRB Standard Operating Procedures

Overview ICH GCP E6(R2) Integrated Addendum

GCP: Investigator Responsibilities. Susan Tebbs Nicola Kaganson

The GCP Perspective on Study Monitoring

Prepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department

SOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils

Good Clinical Practice: A Ground Level View

Study Management PP STANDARD OPERATING PROCEDURE FOR Safeguarding Protected Health Information

Human Research Protection Program Institutional Review Board

Quality Assurance and Site Monitoring Visits. Introduction. Training Outline

HIC Standard Operating Procedure. For-Cause Audits of Human Research Studies

Setting up a CITI account for users not enrolled at or employed by Georgia Tech. Georgia Institute of Technology December 2016

The SOP applies to all human subject research falling under the purview of the University of Missouri Institutional Review Board.

# version e1.0 Administration Handling Participant (Donor) Complaints

Auditing of Clinical Trials

FDA Medical Device Regulations vs. ISO 14155

QUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES

*Applicable to: Beaumont Health. Document Type: Policy

The Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.

University of Virginia Standard Operating Procedures for the Human Research Protection Program

Risk Assessment and Monitoring

16 STUDY OVERSIGHT Clinical Quality Management Plans

EXEMPT RESEARCH. 1. Overview

Document Title: Informed Consent for Research Studies

TITLE: External Audits of DF/HCC Clinical Research SOP #: AUD-102 (formerly QA-706) Page: 1 of 8 Effective Date: 1/14/2016

How to Prepare for Federal Inspections and What to Expect

Office of Human Research Office of Human Research Policy and Procedure Manual. Version: 4/4/18

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)

STANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager

Human Subject Regulations Decision Charts

NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION

IRB review of international research. Pre-conference P1 FCPA 3 rd Party Due Diligence for Health Entities. Today

Central Michigan University Standard Operating Procedures Human Research Protection Program

Documenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC

Ethics Committee Composition Roles & Responsibilities. Dr Girish Dayma Dr Sanjay Juvekar KEM Hospital Research Centre Pune

Document Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator

Tufts Medical Center (Tufts MC) and Tufts University Health Sciences (TUHS) IRB Western IRB (WIRB) Submission Policy

STANDARD OPERATING PROCEDURE SOP 325

First inspection of a Legal Representative in the EU by local authority

RESEARCH SUPPORTED BY A DEPARTMENT OF DEFENSE (DOD) COMPONENT

Study Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting

Informed Consent SOP Number: 25 Version Number: 6.0 Effective Date: 1 st September 2017 Review Date: 1 st September 2019

Standard Operating Procedures (SOP) Research and Development Office

Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics

APEC Preliminary Workshop: Review of Drug Development in Clinical Trials

Genesis Health System. Institutional Review Board. Standard Operating Procedures

Audits/Inspections Be Prepared for Anything

Joint R&D Support Office SOP S-2011 UHL

Solutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session

Solutions for GCP Compliance Challenges

Record or Document Type Retention Period Relevant Legal Citation(s) IRB Records: Training Records;

Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan

Joint Statement on the Application of Good Clinical Practice to Training for Researchers

FDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations

Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026

Conducting Monitoring Visits for Investigator-Initiated Trials (IITs)

Institutional Review Board Standard Operating Procedures. Education and Training on Human Subject Research Date Last Revised: OVERVIEW

Document Title: Study Data SOP (CRFs and Source Data)

National Cancer Institute. Central Institutional Review Board. Standard Operating Procedures

Research Staff Training

Standard Operating Procedure (SOP) Research and Development Office

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Session 3 FDA Audits and Findings

CLOSE OUT VISIT REPORT (NO CRF TO MONITOR)

TITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18

I. Scope This policy defines unanticipated problems and adverse events and establishes the reporting process and timeline.

Research Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004

HonorHealth Research Institute. Investigator Manual. July 27, Version 3.0

Document Title: Document Number:

Clinical Trial Readiness Checklist October 2014

Take a Course of Action.

SECNAVINST E ONR Dec 2017 SECNAV INSTRUCTION E. From: Secretary of the Navy. Subj: HUMAN RESEARCH PROTECTION PROGRAM

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS

SECNAVINST D BUMED-M00R 6 November 2006

Clinical Research Professionals

4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.

Biomedical IRB MS #

University of South Carolina. Unanticipated Problems and Adverse Events Guidelines

Essential Documents It s Not Just a Binder!

Transcription:

TITLE: Standard Operating Procedure (SOP) External Inspections or Audits NUMBER: NSHA REB-SOP-9-002 Effective Date: April 2014 Revision: September 29, 2017 Applies To: Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers. 1. PURPOSE: The purpose of this standard operating procedure (SOP) is to describe the procedures to be followed before, during and following an external inspection or audit. 2. POLICY: Health Canada has the authority to inspect Investigator sites conducting clinical trials that fall under the Regulations to assess compliance with relevant regulations and guidelines. The US Food and Drug Administration (FDA) has the authority to audit Investigator sites involved in studies conducted under a US Investigated New Drug Application (IND) or Investigational Device Exemption (IDE) to assess compliance with relevant regulations and guidelines. The US Office for Human Research Protection (OHRP) has the authority to audit Canadian Research Ethics Boards (REB s) that oversee studies that are supported by the US federal government. Sponsors, funding entities, or others authorized by regulations or agreements with the organizations may have the authority to audit or inspect research-related documents and procedures. These audits or inspections may involve the REB; therefore, the REB must have policies in place for dealing with external audits or inspections. The Principal Investigator is responsible for notifying the REB of any planned audits or inspections of research projects overseen by the REB. 3. DEFINITIONS: Audit: A systematic and independent examination of study-related activities and documents, to determine whether the evaluated activities were conducted, and the data were recorded, analyzed, and accurately reported according to the protocol and all applicable standards.

MREB-SOP-9-001 Page 2 of 5 External Audit: An audit performed by an external party such as the study sponsor (or its agents). Informed Consent Form (ICF): A document confirming the research participant s willingness to participate in a particular research study. Inspection: The act by a regulatory authority of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority to be related to the research study. 4. PROCEDURES: 4.1. Preparing for an Inspection or Audit 4.1.1. The REB Chair or designee will confirm with the Sponsor and/or the Principal Investigator (or inspector/auditor, as applicable) regarding the agreed dates and times of the inspection/audit, and verify the purpose of the inspection/audit, the applicable project(s) undergoing inspection/audit and the inspection/audit plan and procedures; 4.1.2. The REB Chair or designee will notify the REB Executive Committee and the REB Office Personnel of the inspection/audit; 4.1.3. The REB Chair or designee will review the inspection/audit procedures with the Executive Committee and REB Office Personnel and conduct a thorough review of the required documentation; 4.1.4. The REB Chair or designee will arrange for access to the appropriate documents for the inspector/auditor; 4.1.5. The REB Chair or designee will confirm that the Executive Committee and REB Office Personnel are available for interviews or to assist the inspector/auditor; 4.1.6. The REB Chair or designee will arrange for a suitable work area (e.g. private and with sufficient space, with access to a computer and in close proximity to a photocopier and telephone) for the inspector/auditor. 4.2. Participating in an Inspection or an Audit 4.2.1. The REB Chair or designee will meet with the inspector/auditor as scheduled. Prior to being granted access to the research-specific REB documentation, the inspector/auditor must exhibit proof of authority or authorization to conduct the inspection/audit; 4.2.2. The REB Chair or designee will record the name, contact information and title of the inspector/auditor and retain any written notices of inspection/audit for the REB files;

MREB-SOP-9-001 Page 3 of 5 4.2.3. The REB Chair or designee will provide a brief orientation to the inspector/auditor of REB procedures; 4.2.4. The REB Chair or designee will provide access to the research-specific documents requested by the inspector/auditor and maintain a list of the documents reviewed; 4.2.5. The REB Chair or designee will accompany the inspector/auditor at all times while in confidential areas of the REB office and/or the organization; 4.2.6. The REB Chair or designee will ensure that the inspector/auditor s questions are answered by the most appropriate personnel. The REB Chair or designee, REB Office Personnel and REB members must make every reasonable effort to be available and to accommodate the requests of the inspector/auditor; 4.2.7. The REB Chair or designee will request meetings with the inspector/auditor at the end of each day, as needed, to discuss any observations. If questions are asked or observations are made during the daily meetings, the REB Chair or designee will research the issues and provide the inspector/auditor with clarification as soon as possible once the information is available; 4.2.8. The REB Chair or designee will ensure that the required personnel are present at the exit interview 4.2.9. The REB Chair or designee will record any observations of the inspector/auditor and any discussion and ascertain when/if a written response is required. 4.3. Follow-up after an Inspection or Audit 4.3.1. The REB Chair or designee will request a copy of the report from the Researcher; 4.3.2. The REB Chair or designee and any other designated individuals will review any findings relevant to the REB and prepare a written response to each item or observation, including any clarification or corrective action that will be taken. The response to the inspector/auditor should be coordinated through the appropriate channels (e.g., the sponsor via the Investigator); 4.3.3. The REB Chair or designee and any other designated individuals will institute any correction actions as applicable and revise the REB SOPs as needed; 4.3.4. The REB Chair or designee will file the inspection/audit and response documents in the appropriate files (e.g. quality assurance).

MREB-SOP-9-001 Page 4 of 5 5. REFERENCES: I. The International Conference on Harmonization (ICH) Guidelines for Good Clinical Practice (GCP), Section 5.19.1, 5.19.2(b), 5.19.3(b)(c). II. US Food and Drug Administration (FDA) Code of Federal Regulations (CFR) Title 45 Part 46.115(b) III. US Food and Drug Administration (FDA) Code of Federal Regulations (CFR) Title 21 Part 56.115(b) 6. RELATED DOCUMENTS: I. Policy & Procedure RS 04-002 Regulatory Inspections and Investigations of II. III. Research Studies; Policy & Procedure RS 04-003 External Audits of Research Studies; http://policy.nshealth.ca/site_published/dha9/document_render.aspx?docum entrender.idtype=6&documentrender.genericfield=&documentrender.id= 43305

MREB-SOP-9-001 Page 5 of 5 Version History Effective Date Major Revisions (e.g. Standard 4 year review) June 3, 2016 September 29, 2017 Minor Revisions (e.g. spelling correction, wording changes, etc.) Reflect the change from nine DHA s to one Harmonize with CAREB/N2 SOP s